Deutsche Bank AG Has $19.85 Million Position in Innoviva Inc (NASDAQ:INVA)

Deutsche Bank AG boosted its holdings in shares of Innoviva Inc (NASDAQ:INVA) by 36.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,137,370 shares of the biotechnology company’s stock after acquiring an additional 304,583 shares during the period. Deutsche Bank AG owned 1.12% of Innoviva worth $19,845,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. TrimTabs Asset Management LLC acquired a new position in shares of Innoviva in the 4th quarter valued at $1,116,000. Amalgamated Bank acquired a new position in Innoviva in the 4th quarter worth $194,000. Assenagon Asset Management S.A. acquired a new position in Innoviva in the 4th quarter worth $3,447,000. Financial Gravity Companies Inc. acquired a new position in Innoviva in the 4th quarter worth $40,000. Finally, Geode Capital Management LLC boosted its stake in Innoviva by 3.0% in the 4th quarter. Geode Capital Management LLC now owns 799,879 shares of the biotechnology company’s stock worth $13,957,000 after purchasing an additional 23,141 shares during the period. 79.00% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:INVA traded down $0.21 on Friday, hitting $14.73. 920,117 shares of the company’s stock were exchanged, compared to its average volume of 1,101,984. The company has a debt-to-equity ratio of 2.41, a current ratio of 34.92 and a quick ratio of 34.92. Innoviva Inc has a 52 week low of $13.07 and a 52 week high of $20.54. The stock has a market capitalization of $1.42 billion, a PE ratio of 4.17 and a beta of 1.82.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.36 by ($0.05). Innoviva had a negative return on equity of 508.18% and a net margin of 151.36%. The business had revenue of $55.18 million for the quarter. On average, analysts anticipate that Innoviva Inc will post 1.46 earnings per share for the current fiscal year.

INVA has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Innoviva from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Friday, February 8th. BidaskClub lowered shares of Innoviva from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 2nd. Finally, ValuEngine raised shares of Innoviva from a “sell” rating to a “hold” rating in a research note on Monday, February 25th.

In other news, insider Geoffrey Hulme bought 7,000 shares of the company’s stock in a transaction dated Friday, February 15th. The shares were bought at an average cost of $14.80 per share, with a total value of $103,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director George Bickerstaff bought 10,000 shares of the company’s stock in a transaction dated Thursday, February 21st. The stock was purchased at an average cost of $14.90 per share, for a total transaction of $149,000.00. Following the completion of the acquisition, the director now owns 38,762 shares in the company, valued at approximately $577,553.80. The disclosure for this purchase can be found here. Insiders have acquired a total of 32,000 shares of company stock worth $491,100 over the last three months. Insiders own 0.18% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Deutsche Bank AG Has $19.85 Million Position in Innoviva Inc (NASDAQ:INVA)” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/04/innoviva-inc-inva-shares-bought-by-deutsche-bank-ag.html.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Further Reading: Price to Earnings Ratio (PE) Basics

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.